We are hiring. We cannot wait to meet you to share our passion in Transcriptomics! Interested candidates should email a cover letter and resume to email@example.com
Looking forward to sharing our insights from 10+ years of extracellular microRNA (and recently long RNA as well) biomarker discovery and diagnostic test development with the COST Action AtheroNET group. Date: 19.02.2024 Time: 19:30 CET Registration Link: https://lnkd.in/dVDDYKcA Reach out to Matthias directly after his webinar and discuss our latest developments and how TAmiRNA’s miND spike ins and small RNA sequencing service can assist your business!
One last look back at 2023 before we turn our attention to our goals for 2024: last year brought us progress in many areas, from the development of new laboratory and data analyses to the implementation of hepatomiR® in routine clinical diagnostics and the establishment of important partnerships. Our thanks go to the entire (growing) TAmiRNA team, and our customers and partners! We look forward to working together and to our joint successes in 2024!
TAmiRNA has entered an exclusive distribution agreement with Techtum Lab for the sales of their products in the Nordics. Techtum Lab is a full service supplier and partner to clinical and research molecular biology laboratories and looks back at >45 years of experience in the Nordic region. TAmiRNA complements Techtum’s NGS portfolio with the miND Spike-Ins, a unique set of controls for small RNA sequencing experiments. Furthermore, Techtum partners with TAmiRNA to make customized RNA sequencing services accessible to those customers who are looking for external support with analysing their sample’s RNA content.
Matthias Hackl, CEO/CSO of TAmiRNA, visited Japan between November 11th and 18th to join Summit Pharmaceutical international to introduce TAmiRNA to 12 medium- and large-size pharmaceutical companies. Matthias presented information on microRNA and mRNA biomarker discovery in liquid biopsies using TAmiRNA´s unique miND® pipeline for absolute quantification of microRNAs. In addition, Matthias joined a seminar on “Manufacturing and omic-based characterization of extracellular vesicles as drug products” organized by the local partner Summit Pharmaceutical International. In his talk, Matthias explained to >70 representatives from Japanese Universities and Pharmaceutical industry TAmiRNA’s the advantages of full molecular characterization of exosomes and extracellular vesicles (EVs) to determine EV composition, consistency, and mode-of-action.
TAmiRNA Scientific Consultant Magdalena Mecking is attending the Extracellular Vesicles Forum on Oct 10th – 11th in Cambridge. Stop by one of her posters and learn more about how TAmiRNA’s service may benefit your EV project! Reach out to Magdalena directly and discuss our latest developments and how TAmiRNA's services can assist your business!
TAmiRNA CEO/CSO Matthias Hackl will attend the RNA Leaders conference in Boston next week to speak about how cell-free RNA biomarkers can be incorporated in pre-clinical and clinical development to inform about drug safety, drug targeting, and drug efficacy. Reach out to Matthias directly to meet with him before or after his presentation on Thursday, Sept. 7th at 4:30 pm ET and discuss our latest developments and how TAmiRNA's services can assist your business!
TAmiRNA will be a significant contributor to the inaugural joint European meeting of the ISSX and DMDG respectively focused on xenobiotics and drug metabolics. Dr. Matthias Hackl, CEO and co-founder, will take part in the discussions of Symposium 4: ‘MicroRNAs as Biomarkers of Clinical Drug-induced Organ Injury’ (Tuesday, June 13, 1000-1200 hrs). Dr. Hackl’s presentation ‘miRNA Biomarker Development: Pitfalls and Best Practices for Discovery and Validation’ will highlight the increasing scope to apply TAmiRNA’s recently developed MicroRNA Next-Generation Sequencing Discovery (miND®) technology and associated miND® spike-ins to identify novel circulating microRNA biomarkers of CNS and other organ damage, as well as comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs). Take advantage, [...]
TAmiRNA Senior Scientist Dr. Kseniya Khamina-Kotisch will present Poster 46 ‘Identification of novel circulating MicroRNA Biomarkers of Central Nervous System Damage by absolute quantitation using a MicroRNA Next-Generation Sequencing Discovery (miND) Assay’. She will also present Poster 66: ‘Comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs) in cells, plasma, urine, and extracellular vesicles’. Take advantage, meet Kseniya and discuss our latest developments and how TAmiRNA's miND spike ins and services can assist your business!
The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release